Physician profile
Michael Hamer
NPI 1851745335
$4,735.45
in general payments reported to CMS, 2019-2025
36 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $262 · 2021: $888 · 2022: $711 · 2023: $604 · 2024: $1,098 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,290.50 | 2021-2025 | |
| Biogen, INC. | $593.55 | 2020-2025 | Tysabri, Vumerity, Avonex |
| Pfizer INC. | $359.72 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $286.58 | 2020-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $202.53 | 2020-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $200.93 | 2021-2022 | |
| Amgen INC. | $196.92 | 2020-2025 | Uplizna, Aimovig |
| Ucb, INC. | $155.84 | 2022-2024 | Briviact |
| Lilly USA, LLC | $150.79 | 2020-2025 | Emgality, Reyvow |
| Argenx US, INC. | $145.33 | 2022-2025 | Vyvgart |
| Genentech USA, INC. | $117.89 | 2022-2024 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $108.19 | 2021-2025 | |
| Axsome Therapeutics, INC. | $99.47 | 2025 | Symbravo |
| Lundbeck LLC | $88.54 | 2020-2025 | Vyepti |
| Greenwich Biosciences, INC. | $62.67 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $62.59 | 2021-2023 | Zeposia |
| Horizon Therapeutics Plc | $57.03 | 2021-2023 | Uplizna |
| Eisai INC. | $55.07 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $50.56 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $40.79 | 2021-2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $38.66 | 2020-2022 | |
| Sk Life Science, INC. | $38.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $36.90 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.43 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $33.49 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $31.54 | 2025 | Rexulti |
| Allergan, INC. | $26.27 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.25 | 2024 | Hyqvia |
| Tanabe Pharma America, INC. | $20.91 | 2024 | |
| Neurelis, INC. | $20.88 | 2023 | Valtoco |
| Avion Pharmaceuticals | $20.75 | 2022 | |
| Emd Serono, INC. | $18.96 | 2025 | |
| Ani Pharmaceuticals, INC. | $18.75 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $17.62 | 2023 | Nourianz |
| Jazz Pharmaceuticals INC. | $16.57 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.